Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GNMSF Genmab A/S	$224.30	$201.52	$170.00 ▼ $292.80	$14.82B	0.92	2,763 shs	N/A
SMMT Summit Therapeutics	$19.78 -1.9%	$23.61	$6.78 ▼ $36.91	$14.69B	-1.06	3.63 million shs	2.89 million shs
TEVA Teva Pharmaceutical Industries	$17.00 -4.0%	$15.97	$12.47 ▼ $22.80	$19.49B	0.6	10.19 million shs	13.23 million shs
ZLDPF Zealand Pharma A/S	$74.13	$66.46	$57.97 ▼ $141.74	$5.26B	0.74	917 shs	80 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GNMSF Genmab A/S	0.00%	+2.83%	+18.80%	+7.38%	-14.56%
SMMT Summit Therapeutics	+2.96%	+2.18%	-18.08%	-3.03%	+144.36%
TEVA Teva Pharmaceutical Industries	+2.14%	+2.52%	+1.09%	+7.91%	+2.64%
ZLDPF Zealand Pharma A/S	0.00%	+4.24%	+16.29%	-12.28%	-17.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GNMSF Genmab A/S	0.6132 of 5 stars	0.0	3.0	0.0	0.0	1.6	0.0	1.3
SMMT Summit Therapeutics	2.9081 of 5 stars	4.4	3.0	0.0	0.0	2.0	1.7	0.0
TEVA Teva Pharmaceutical Industries	4.1105 of 5 stars	4.6	5.0	0.8	0.0	2.6	1.7	0.6
ZLDPF Zealand Pharma A/S	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GNMSF Genmab A/S	0.00	N/A	N/A	N/A
SMMT Summit Therapeutics	2.77	Moderate Buy	$35.09	77.66% Upside
TEVA Teva Pharmaceutical Industries	3.20	Buy	$24.44	42.95% Upside
ZLDPF Zealand Pharma A/S	3.67	Strong Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZLDPF, TEVA, SMMT, and GNMSF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	SMMT Summit Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
6/11/2025	SMMT Summit Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$12.00
6/6/2025	TEVA Teva Pharmaceutical Industries	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00
6/2/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00
5/28/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
5/27/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$21.00 ➝ $23.00
5/8/2025	SMMT Summit Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
5/2/2025	SMMT Summit Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $41.00
4/28/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GNMSF Genmab A/S	$3.12B	4.75	$15.27 per share	14.69	$80.53 per share	2.79
SMMT Summit Therapeutics	$700K	20,955.91	N/A	N/A	$0.11 per share	179.56
TEVA Teva Pharmaceutical Industries	$16.62B	1.18	$3.39 per share	5.05	$4.75 per share	3.60
ZLDPF Zealand Pharma A/S	$9.09M	579.17	N/A	N/A	$4.49 per share	16.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GNMSF Genmab A/S	$1.14B	$17.63	12.80	∞	N/A	36.30%	19.75%	16.23%	8/7/2025 (Estimated)
SMMT Summit Therapeutics	-$614.93M	-$0.34	N/A	N/A	N/A	N/A	-85.42%	-52.66%	8/5/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.50	1.44	-9.91%	42.46%	6.65%	7/30/2025 (Estimated)
ZLDPF Zealand Pharma A/S	-$102.18M	-$2.49	N/A	N/A	N/A	-1,725.03%	-15.24%	-13.77%	8/21/2025 (Estimated)

Latest ZLDPF, TEVA, SMMT, and GNMSF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	GNMSF Genmab A/S	$1.88	$3.05	+$1.17	$3.05	$761.09 million	$765.14 million
5/8/2025	Q1 2025	ZLDPF Zealand Pharma A/S	-$0.77	-$0.67	+$0.10	-$0.67	$248.61 million	$1.14 million
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GNMSF Genmab A/S	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	5.91%	N/A	N/A	N/A
ZLDPF Zealand Pharma A/S	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GNMSF Genmab A/S	N/A	5.25	5.24
SMMT Summit Therapeutics	N/A	8.31	8.31
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75
ZLDPF Zealand Pharma A/S	0.03	35.49	35.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GNMSF Genmab A/S	N/A
SMMT Summit Therapeutics	4.61%
TEVA Teva Pharmaceutical Industries	54.05%
ZLDPF Zealand Pharma A/S	N/A

Insider Ownership

Company	Insider Ownership
GNMSF Genmab A/S	1.54%
SMMT Summit Therapeutics	84.90%
TEVA Teva Pharmaceutical Industries	0.49%
ZLDPF Zealand Pharma A/S	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GNMSF Genmab A/S	1,660	66.08 million	65.06 million	Not Optionable
SMMT Summit Therapeutics	110	742.67 million	86.28 million	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.15 billion	1.13 billion	Optionable
ZLDPF Zealand Pharma A/S	340	71.02 million	N/A	Not Optionable

ZLDPF, TEVA, SMMT, and GNMSF Headlines

Recent News About These Companies

Analysts Set Expectations for OTCMKTS:ZLDPF FY2025 Earnings

June 13 at 2:17 AM | americanbankingnews.com

Cantor Fitzgerald Comments on OTCMKTS:ZLDPF FY2026 Earnings

June 12 at 8:49 AM | marketbeat.com

FY2025 EPS Forecast for Zealand Pharma A/S Raised by Analyst

June 11 at 8:26 AM | marketbeat.com

Cantor Fitzgerald Predicts OTCMKTS:ZLDPF FY2025 Earnings

May 24, 2025 | marketbeat.com

Zealand CEO: Oral weight loss meds are not the future for treating obesity

May 15, 2025 | seekingalpha.com

Zealand Pharma A/S (ZLDPF) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

Zealand Pharma AS (ZLDPF) Q1 2025 Earnings Call Highlights: Strategic Collaborations and ...

May 9, 2025 | finance.yahoo.com

Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit

May 2, 2025 | cnbc.com

Zealand Pharma AS (ZLDPF) Stock Jumps 8.0%: Will It Continue to Soar?

May 1, 2025 | zacks.com

Zealand Pharma begins mid-stage trial for obesity drug candidate in people with type 2 diabetes

April 24, 2025 | reuters.com

Zealand Pharma appoints Utpal Singh as Chief Scientific Officer

April 23, 2025 | contractpharma.com

Zealand Pharma appoints Utpal Singh as CSO

April 23, 2025 | markets.businessinsider.com

Zealand Pharma Hires Lilly Executive as Biotech Ramps Up in Obesity

April 23, 2025 | msn.com

Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025

April 19, 2025 | finance.yahoo.com

Zealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With Roche

April 11, 2025 | wsj.com

Gubra’s obesity drug trial success weighs on Zealand Pharma stock

April 2, 2025 | investing.com

Zealand Pharma upgraded to Overweight from Equal Weight at Morgan Stanley

March 21, 2025 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vicarious Surgical (RBOT), Alkermes (ALKS) and Zealand Pharma (OtherZLDPF)

March 18, 2025 | markets.businessinsider.com

Roche-Zealand deal is the latest to boost obesity space

March 12, 2025 | msn.com

Zealand Pharma's new drug petrelintide will help people lose weight: CEO

March 12, 2025 | youtube.com

Roche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidate

March 12, 2025 | cnbc.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZLDPF, TEVA, SMMT, and GNMSF Company Descriptions

Genmab A/S OTCMKTS:GNMSF

$224.30 0.00 (0.00%)

As of 06/12/2025

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Summit Therapeutics NASDAQ:SMMT

$19.78 -0.38 (-1.88%)

Closing price 04:00 PM Eastern

Extended Trading

$19.88 +0.09 (+0.48%)

As of 04:45 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries NYSE:TEVA

$17.00 -0.71 (-4.03%)

Closing price 03:59 PM Eastern

Extended Trading

$17.14 +0.14 (+0.81%)

As of 04:45 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Zealand Pharma A/S OTCMKTS:ZLDPF

$74.13 0.00 (0.00%)

As of 06/12/2025

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time